Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cresset Announces Release of forgeV10.1

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Powerful new capabilities for computational chemistry workbench.

Cresset has announced the release of a new version of its computational chemistry workbench forgeV10.

This release is the first major update following the launch of forgeV10 in 2012 and brings new features and many improvements.

New in forgeV10.1 are:
• flexible handling of multiple reference molecules giving improved results during analysis of structure activity relationships.
• enhanced capabilities for viewing molecules in 3D.
• ability to download protein crystal structure files and rapidly split them into protein and ligand.

“forgeV10 has been an instant hit with our customers. They use it for gaining deep insights into structure activity relationships, for virtual screening on desktop hardware and to develop detailed pharmacophores for the design of compounds and compound libraries,” says Dr Tim Cheeseright, Cresset’s Director of Products.

He adds, “We have had many customer requests for new features, particularly for more control over how molecules are compared. We have listened carefully to our customers and are proud to introduce significant scientific enhancements in forgeV10.1, as well as streamlining the design of new compounds and interpretation of complex SAR.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cresset Donates to Novartis’ TExts to Sub-Saharan Africa Project
Project donates textbooks to Kenyan university libraries.
Tuesday, September 30, 2014
CloudScientific Appointed as Cresset’s Distributor in China
CloudScientific appointed as distributor of computational chemistry software.
Friday, July 11, 2014
Locating and Explaining ‘Activity Cliffs’ in SAR Datasets
Activity Miner from Cresset is an intuitive SAR interpretation tool, identifying key 3D structural and electrostatic changes that impact molecular activity.
Monday, September 16, 2013
Victrix CMCC Chooses Cresset’s Software for Drug Discovery Consulting Projects
Cresset’s software will help Victrix clients to carry out structure based drug design projects.
Friday, June 28, 2013
Cresset Announces new International Sales Team
Cresset has expanded its computational chemistry software sales team in the U.S. and Europe.
Thursday, September 09, 2010
Cresset Announces Appointment of Rob Scoffin as new CEO
Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.
Monday, April 26, 2010
Cresset Expands Sales Pipeline Potential through CambridgeSoft Alliance
CambridgeSoft sells Cresset’s FieldAlign and FieldTemplater products using its direct, telesales and ecommerce channels.
Monday, April 20, 2009
Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos